<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03254966</url>
  </required_header>
  <id_info>
    <org_study_id>SHR0302-201</org_study_id>
    <nct_id>NCT03254966</nct_id>
  </id_info>
  <brief_title>Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Safety and Efficacy of SHR0302 in Patients With Moderate to Severe Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of SHR0302 tablets (SHR0302) in subjects with moderate to
      severe active rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving an American College of Rheumatology (ACR)20 response at Week 12</measure>
    <time_frame>Baseline - Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving an American College of Rheumatology (ACR)20 response at Week 24</measure>
    <time_frame>Baseline - Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving an American College of Rheumatology (ACR)50 response at Week 12</measure>
    <time_frame>Baseline - Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving an American College of Rheumatology (ACR)50 response at Week 24</measure>
    <time_frame>Baseline - Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving an American College of Rheumatology (ACR)70 response at Week 12</measure>
    <time_frame>Baseline - Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving an American College of Rheumatology (ACR)70 response at Week 24</measure>
    <time_frame>Baseline - Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving DAS28-3（CRP）＜2.6 at Week 12</measure>
    <time_frame>Baseline - Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving DAS28-3（CRP）＜2.6 at Week 24</measure>
    <time_frame>Baseline - Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Health Assessment Questionaire (HAQ-DI) at week 12</measure>
    <time_frame>Baseline - Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Health Assessment Questionaire (HAQ-DI) at week 24</measure>
    <time_frame>Baseline - Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SHR0302 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0302 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0302 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0302 dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>SHR0302 dose level 1</arm_group_label>
    <arm_group_label>SHR0302 dose level 2</arm_group_label>
    <arm_group_label>SHR0302 dose level 3</arm_group_label>
    <arm_group_label>SHR0302 dose level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female subjects who are 18 - 70 (inclusive) years of age on the day of signing
             informed consent

          -  have a diagnosis of RA meeting the 2010 ACR/EULAR criteria of RA and ACR functional
             class I-III

          -  have ≥6 swollen joints (from a 66-joint count) and ≥8 tender joints (from a 68-joint
             count) at Screening and at Baseline, Screening serum c-reactive protein (CRP)or hsCRP
             ＞ 1.2 x upper limit of laboratory normal range (ULN),or erythrocyte sedimentation rate
             (ESR) ＞ 28 mm/h

          -  have not used any disease modifying anti-rheumatic drug (DMARD) or have an inadequate
             response to one or more kinds of conditional DMARDs (methotrexate, leflunomide,
             Chloroquine, hydroxychloroquine, sulfasalazine, minocycline, penicillamine, auranofin
             or injection gold preparation, and iguratimod) due to lack of efficacy or toxicity,
             and have agreed to be washed out from these conditional DMARDs for a period of at
             least 7 t1/2s prior to randomization, with the exception of antimalarials, which must
             be at a stable dose for at least 12 weeks prior to randomization

          -  Body mass index (BMI = weight/height squared (kg/m2)) within the range of 18 to 35,

        Exclusion Criteria:

          -  current or previous RA treatment with a jak inhibitor

          -  current or previous RA treatment with a biologic DMARD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofeng Zeng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Lan</last_name>
    <phone>86-21-61049928</phone>
    <phone_ext>803</phone_ext>
    <email>lanyang@shhrp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Chen</last_name>
    <phone>86-21-61049928</phone>
    <phone_ext>803</phone_ext>
    <email>cheny@shhrp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yan sun</last_name>
      <phone>86-010-69158355</phone>
      <email>xieheyaoli@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaofeng Zeng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

